Onco3R Therapeutics Appoints Lawrence Blatt as Chair of the Board for Onco3R Therapeutics

Company Overview - Onco3R Therapeutics is a clinical-stage immunology and oncology biotech company focused on transforming patients' lives with best-in-class medicines [1][6] - The company is based in Leuven, Belgium, and has over 150 years of combined R&D experience among its team [6] Leadership Appointment - Lawrence M. Blatt, PhD, MBA has been appointed as Chair of the Board of Directors [1] - Dr. Blatt has extensive experience in strategic leadership, drug development, and operations, previously serving as CEO of Aligos Therapeutics and holding key positions at Janssen Pharmaceutical Companies [2][3] Product Development - Onco3R is developing O3R-5671, a highly selective SIK3 inhibitor designed to treat autoimmune diseases while avoiding toxicities associated with SIK1 and SIK2 [4] - Preclinical data indicates that O3R-5671 can inhibit pro-inflammatory cytokines and promote immunomodulatory cytokines, suggesting its potential for treating conditions like ulcerative colitis, Crohn's Disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis [4] Clinical Trials - A Phase 1 trial for O3R-5671 is underway, evaluating its safety and pharmacokinetics in healthy volunteers, with plans for subsequent patient trials across various autoimmune diseases starting in 2026 [5]